Tocilizumab for COVID-19 Pneumonia in a Patient With Non–Small-cell Lung Cancer Treated With Chemoimmunotherapy

Bonomi, Maria; Maltese, Mariangela; Brighenti, Matteo; Muri, Margherita; Passalacqua, Rodolfo

doi:10.1016/j.cllc.2020.08.002

Cited by 13 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to note that none of these trials evaluating these treatments reported the presence of cancer as a pre-existing condition (https://www.covid19treatmentguidelines.nih.gov/management/clinical-1248management/hospitalized-adults--therapeutic-management/) (141) (57) (142) (143) (144). Specific to tocilizumab, there have been reports of its successful use in patients with cancer, (145,146) however, concomitant immunotherapy poses a theoretical risk due to hyperactivation of the immune system causing cytokine storm (147).…”

Section: General Management For Hospitalized Patientsmentioning

confidence: 99%

Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer

Elkrief¹,

Wu²,

Jani³

et al. 2021

Cancer Discov

View full text Add to dashboard Cite

The ongoing COVID-19 pandemic has left patients with current or past history of cancer facing disparate consequences at every stage of the cancer trajectory. This comprehensive review offers a landscape analysis of the current state of the literature on COVID-19 and cancer including the immune response to COVID-19, risk factors for severe disease, and impact of anticancer therapies. We also review the latest data on treatment of COVID-19 and vaccination safety and efficacy in patients with cancer, as well as impact of the pandemic on cancer care, including the urgent need for rapid evidence generation and realworld study designs.

show abstract

Section: General Management For Hospitalized Patientsmentioning

confidence: 99%

Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer

Elkrief¹,

Wu²,

Jani³

et al. 2021

Cancer Discov

View full text Add to dashboard Cite

show abstract

“…After treatment, the oxygen support was decreased and CT scan showed ground glass opacity reduction. Finally, the patient was discharged, and he resumed chemoimmunotherapy without complications [ 24 ]. This strategy is compatible with the ESMO guideline that COVID19 treatment should be prioritized and chemoimmunotherapy can be resumed after stabilization of COVID-19.…”

Section: Clinical Lung Injuries In Patients With Covid-19mentioning

confidence: 99%

COVID-19 and the lungs: A review

Chan

et al. 2021

Journal of Infection and Public Health

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) attacks pulmonary alveolar cells via angiotensin-converting enzyme 2 (ACE2) receptors and causes pulmonary infections that result in coronavirus disease (COVID-19), inducing immune responses that can result in severe pneumonia. We reviewed the clinical experiences of lung diseases during the COVID-19 pandemic to offer insights into the adaptations made by experts in the diagnosis and treatment of these comorbidities. Various lung comorbidities increase the severity of COVID-19 and associated mortality by amplifying ACE2 expression. Additionally, the COVID-19 pandemic has changed the use of routine diagnostic pulmonary imaging methods, making chest sonography scoring the most convenient, as it can be conducted bedside. Treatment protocols for SARS-CoV-2 infection and the underlying lung diseases are also affected owing to potential interactions. The optimal diagnostic methods and treatment protocols for lung diseases have been adapted worldwide to increase survival rates and attenuate acute lung injuries during the COVID-19 pandemic.

show abstract

“…Large multi-centered studies are also needed to investigate the impact of other treatments including Tocilizumab and steroids on the morbidity and mortality of cancer patients with covid-19. While limited evidence is available on treatment with tocilizumab for COVID-19 [45], data on steroids impact is con icting [38,46]. In our study population, these drugs were given by ED physicians to patients who are deemed sicker.…”

Section: Discussionmentioning

confidence: 99%

Predictors of ICU Admission in Adult Cancer Patients Presenting to the Emergency Department for COVID-19 Infection: A Retrospective Study

kalot

Khalifeh

Estelly

et al. 2022

Preprint

View full text Add to dashboard Cite

Study Objective: Adult cancer patients with COVID-19 were shown to be at higher risk of ICU admission. Previously published prediction models showed controversy and enforced the importance of heterogeneity among different populations studied. The aim of this study was to detect the predictors of ICU admission for adult COVID-19 patients with cancer who present to the emergency department (ED).Methods: Theis a retrospective cohort study. It was conducted on adult cancer patients older than 18 years who presented to the EDof the American University of Beirut MedicalCenter from February 21, 2020, till February 21, 2021, and were found to have COVID-19 infection. Relevant electronic data were extracted. The association between different variables and ICU admission was tested. Logistic regression was done to adjust for confounding variables. P value less than 0.05 was considered significant.Results: Eighty-nine distinct patients were included. About 37% were admitted to the ICU (n=33). Higher ICU admission was seen in patients who had received chemotherapy within one month, had a respiratory rate at triage > 22 breaths per minute, an oxygen saturation < 95%, and/or a higher CRP upon presentation to the ED. After adjusting for confounding variables only recent chemotherapy and higher respiratory rate at triage were significantly associated with ICU admission. Conclusion: Physicians need to be vigilant when taking care of covid infected oncology patients. Patients who are tachypneic at presentation and those who have had chemotherapy within one month are at high risk for ICU admission.

show abstract

Tocilizumab for COVID-19 Pneumonia in a Patient With Non–Small-cell Lung Cancer Treated With Chemoimmunotherapy

Cited by 13 publications

References 16 publications

Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer

Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer

COVID-19 and the lungs: A review

Predictors of ICU Admission in Adult Cancer Patients Presenting to the Emergency Department for COVID-19 Infection: A Retrospective Study

Contact Info

Product

Resources

About